Skip to main content

Seelos Therapeutics, Inc.

SEELDelisted Apr 4, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001017491

Seelos Therapeutics, Inc. was delisted on Apr 4, 2025; its insiders filed their last Form 4 on Mar 1, 2024; 23 institutions reported holding it in 13F filings for Q2 2024, worth $129.4K in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
23
Q2 2024, −13 vs. previous quarter
13F value
$129.4K
Reported value at the end of Q2 2024
Superinvestors holding
0
At the end of Q2 2024

Superinvestors holding SEEL, Q2 2024

Go to the superinvestors tab

No superinvestor reported holding SEEL at the end of Q2 2024.

Latest insider trades

Open-market purchases and sales by Seelos Therapeutics, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 1, 2023 (view filing)Nov 301 dayGolembiewski Michael JosephChief Financial OfficerPPurchase+83.0K$1.21+$100.4K+2,405.8%86.5K after
Dec 1, 2023 (view filing)Dec 1Same dayMehra RajSee RemarksPPurchase+75.8K$1.32+$100.0K+69.3%185.1K after
Dec 1, 2023 (view filing)Dec 1Same dayMehra RajSee RemarksPPurchase+75.8K–––75.8K afterDerivative
Jun 2, 2022 (view filing)Jun 11 dayO'Connor Daniel J.DirectorPPurchase+16.0K$0.61+$9.76KNew position16.0K after
May 27, 2022 (view filing)May 261 dayDalesandro MargaretDirectorPPurchase+35.0K$0.60+$21.0KNew position35.0K after
Mar 31, 2022 (view filing)Mar 31Same dayMehra RajSee RemarksPPurchase+66.7K$0.85+$56.7K+2.1%3.28M after

Top 10 13F holders, Q2 2024

The largest institutional positions in Seelos Therapeutics, Inc. at the end of Q2 2024; share changes are against Q1 2024.

See all 23 holders
Institutions holding SEEL in Q2 2024
InstitutionSharesValue% of portfolioChange in sharesAction
AdvisorShares Investments LLC89,812$55.6K0.01%−372,882−80.6%Reduced
Wealth Effects LLC53,844$32.1K0.01%−412,816−88.5%Reduced
Morgan Stanley22,271$13.3K0.00%−103,793−82.3%Reduced
Modera Wealth Management, LLC21,336$12.7K0.00%−136,281−86.5%Reduced
Geode Capital Management, LLC12,797$7.64K0.00%−89,611−87.5%Reduced
BlackRock Inc.6,975$4.16K0.00%−48,986−87.5%Reduced
Tower Research Capital LLC (TRC)3,859$2.30K0.00%−6,658−63.3%Reduced
Carmichael Hill & Associates, Inc.1,000$5970.00%−7,000−87.5%Reduced
JPMorgan Chase & Co501$3000.00%−3,531−87.6%Reduced
Bank of America Corp472$2820.00%−3,285−87.4%Reduced

Holders of 5% or more of SEEL

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Seelos Therapeutics, Inc..

See all 2 holders and filings
Largest holders of SEEL from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Weber Mark13G10.70%46.5K sharesNewNov 25, 20241 filingNov 25, 2024SEC
Jane Street Group, LLC13G6.60%38.3K sharesNewFeb 14, 20251 filingFeb 14, 2025SEC